NY-SK-CAPITAL-PARTNERS
3.1.2022 18:18:05 CET | Business Wire | Press release
The Heubach Group (“Heubach”, the “Company”), a leading global producer of pigments and SK Capital Partners (“SK Capital”), a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced today the completion of the acquisition of Clariant’s Global Colorants Business (“Clariant Pigments”). The combined business will operate under the Heubach brand, creating a global pigment technology and industry leader.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211231005108/en/
The newly combined Heubach Group is a leading global provider of comprehensive color solutions, supplying a broad portfolio of organic, inorganic, and anti-corrosive pigments, pigment preparations, dyes, colorants and specialty materials. The Company is a technological and quality leader and operates its global business from nineteen manufacturing facilities across Europe, the Americas, Asia and Africa, employing approximately 3,000 people. The headquarters of the Heubach Group will be established in Vienna, Austria.
Johann Heubach, of the Heubach Group, stated, “The new Heubach is a world-class organization with great talent, technology and assets. For us, product excellence and sustainability are core. We are well-positioned to create significant value for our customers and business partners across the many industries we serve.”
Aaron Davenport, a Managing Director of SK Capital, noted, “The combination of Heubach and Clariant Pigments creates an industry leader committed to the highest standards in manufacturing, quality and service. We look forward to supporting management in the growth and improvement of the Company by investing into talent, innovation and market expansion.”
The Heubach Group is excited to announce the appointment of Stefan Doboczky as Chief Executive Officer of the Heubach Group, effective January 10, 2022. Mr. Doboczky joins the Heubach Group having most recently served as CEO of Lenzing AG, a global leader of cellulosic fibers and biochemicals. Prior to Lenzing, Mr. Doboczky was member of the Managing Board of Royal DSM, the Dutch Life Science and Material Science Group, where he spent almost two decades in various general management roles. Mr. Doboczky holds a PhD in Natural Science from the Technical University of Vienna (A), as well as an MBA from IMD in Lausanne (CH). Stefan Doboczky noted, “I am very excited to join the new Heubach Group. I am convinced that by combining these successful businesses we will create a powerful offering for our customers in the pigment and colorant space.”
The Valence Group of Piper Sandler & Co., BofA Securities and Citigroup served as financial advisors to Heubach and SK Capital. Committed financing for the transaction was provided by BofA Securities, Citigroup, HSBC, KeyBanc, Citizens, ING and MUFG. Lenz & Staehelin AG and Kirkland & Ellis LLP acted as legal counsel to Heubach and SK Capital. Milbank LLP acted as legal counsel to Heubach. Homburger AG acted as legal counsel to Clariant and Deutsche Bank AG served as Clariant’s financial advisor.
About Heubach Group
With a tradition of delivering excellence that stretches back over 200 years, the Heubach name is synonymous with innovation, attention to customer needs and reliability in creating colors. Today’s Heubach is a global industry leader in the field of pigments, pigment preparations, dyes, colorants and specialty materials. Heubach is committed to reliable supply of high-quality materials to meet customers demanding production environments. Sustainability is a part of the Heubach DNA. Heubach has a global manufacturing footprint including 19 facilities around the globe and generates approximately €1 billion in annual sales. For more information, please visit www.heubachcolor.com .
About SK Capital
SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $14 billion annually, employs more than 20,000 people globally and operates 191 plants in 32 countries. The firm currently has greater than $5 billion of assets under management. For more information, please visit www.skcapitalpartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211231005108/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
